Compare SS&C Technologies Holdings Inc. Common Stock (SSNC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SS&C Technologies Holdings Inc. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B), while Vertex Pharmaceuticals Incorporated trades at $503 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.4× SS&C Technologies Holdings Inc. Common Stock's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.47% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SSNC | VRTX | |
|---|---|---|
Market Cap | $19.13B | $122.98B |
Volume | 1,333,448 | 1,155,743 |
Sector | Technology | Health |
52-Week High | $89.62 | $557.96 |
52-Week Low | $62.05 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $26.47B | $117.11B |
Dividend Yield | 1.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
